Page 87 - The clinical aspects and management of chronic migraine Judith Anne Pijpers

Withdrawal and botulinum toxin A: a double blind RCT
20. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736-1745. doi:10.1001/ jama.2012.505
21. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):804-814. doi:10.1177/0333102410364676
22. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-814. doi:10.1177/0333102410364677
23. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache J Head Face Pain. 2010;50(6):921-936. doi:10.1111/j.1526- 4610.2010.01678.x
24. Silberstein SD, Blumenfeld AM, Cady RK, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1-2):48-56. doi:10.1016/j.jns.2013.05.003
25. Dougherty C, Silberstein SD. Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management. 2015;15(7):688-692.
26. Olesen J,Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet. 2010;376(9755):1825- 1826. doi:10.1016/S0140-6736(10)62165-4
27. Solomon S. OnabotulinumtoxinA for treatment of chronic migraine: the unblinding problem. Headache. 2013;53(5):824-826. doi:10.1111/head.12065
28. Australian Government. Australian Public Assessment Report for Botulinum toxin Type A Proprietary Product Name : Botox. 2011;(June). https://www.tga.gov.au/sites/default/files/auspar- botox.pdf.
29. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160-164. doi:10.1136/bmj.305.6846.160
30. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: The HIT-6. Qual Life Res. 2003;12(8):963-974. doi:10.1023/A:1026119331193
31. Stewart WF, Lipton RB, Dowson a J, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20-S28. doi:10.1212/WNL.56.suppl_1.S20
32. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. J Psychosom Res. 2002;52(2):69-77. doi:10.1016/S0022-3999(01)00296-3
33. Werkgroep Migraine Richtlijn NVN. Medicamenteuze behandeling migraine en MOH. Richtlijnen database Nvn. 2017.
34. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28(5):484-495. doi:10.1111/j.1468- 2982.2008.01555.x
35. Tassorelli C, Diener HC, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815- 832. doi:10.1177/0333102418758283
36. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091-1100. doi:10.1016/S1474-4422(15)00245-8
37. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017;377(22):2113-2122. doi:10.1212/WNL.0000000000002801
38. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425-434. doi:10.1016/S1474-4422(17)30083-2
39. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. doi:10.1212/WNL.0000000000006640
4
85